# US 10,308,702 B2 · BSL2v2c2-Ig polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,308,702 B2
- Document ID: US10308702B2
- Status: Granted
- Kind: B2
- Application number: 15/218,699
- Filed: 2016-07-25
- Published: 2017-07-06
- Granted: 2019-06-04
- Earliest claimed: 2000-06-06
- Assignees: Bristol-Myers Squibb Comapny
- Applicants: Bristol-Myers Squibb Company
- Inventors: Glen Eugene Mikesell; Han Chang; Robert James Peach
- Web page: https://patentgrep.com/patent/US10308702B2

## CPC

- C07K 14/70532: {B7 molecules, e.g. CD80, CD86}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 39/39533: {against materials from animals}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.

## Claims

### Claim 1

An isolated polypeptide comprising
(a) amino acids 1 to 480 of SEQ ID NO:135;
(b) amino acids 2 to 480 of SEQ ID NO:135; or
(c) amino acids 29 to 480 of SEQ ID NO:135.

### Claim 2 (depends on 1)

The isolated polypeptide of claim 1, wherein said polypeptide is (a).

### Claim 3 (depends on 2)

The isolated polypeptide of claim 2, wherein said polypeptide is encoded by nucleotides 1 to 1440 of SEQ ID NO:134.

### Claim 4 (depends on 1)

The isolated polypeptide of claim 1, wherein said polypeptide is (b).

### Claim 5 (depends on 4)

The isolated polypeptide of claim 4, wherein said polypeptide is encoded by nucleotides 4 to 1440 of SEQ ID NO:134.

### Claim 6 (depends on 1)

The isolated polypeptide of claim 1, wherein said polypeptide is (c).

### Claim 7 (depends on 6)

The isolated polypeptide of claim 6, wherein said polypeptide is encoded by nucleotides 85 to 1440 of SEQ ID NO:134.

### Claim 8

An isolated polypeptide encoded by the isolated nucleic acid in ATCC Deposit No. PTA-1987.

### Claim 9 (depends on 1)

An isolated polypeptide produced by a method comprising:
(a) culturing an isolated recombinant host cell comprising a vector that comprises the coding region encoding the polypeptide of claim 1 under conditions such that said polypeptide is expressed; and (b) recovering said polypeptide.

### Claim 10 (depends on 1)

The isolated polypeptide of claim 1 wherein further comprising a heterologous polypeptide sequence.

### Claim 11

An isolated polypeptide comprising amino acids 1 to 247 of SEQ ID NO:135 fused to the Fc domain of an immunoglobulin.

### Claim 12

An isolated polypeptide comprising amino acids 29 to 246 of SEQ ID NO:135 fused to the Fc domain of an immunoglobulin.

### Claim 13

An isolated polypeptide comprising:
(a) a first sequence comprising amino acids 1 to 246 of SEQ ID NO:135 fused to a second sequence comprising the Fc domain of an immunoglobulin;
(b) a first sequence comprising amino acids 2 to 246 of SEQ ID NO:135 fused to a second sequence comprising the Fc domain of an immunoglobulin; or
(c) a first sequence comprising amino acids 29 to 246 of SEQ ID NO:135 fused to a second sequence comprising the Fc domain of an immunoglobulin.

### Claim 14 (depends on 13)

The isolated polypeptide of claim 13, wherein said first sequence of (a) comprises a sequence encoded by nucleotides 1 to 738 of SEQ ID NO:134.

### Claim 15 (depends on 13)

The isolated polypeptide of claim 13, wherein said first sequence of (b) comprises a sequence encoded by nucleotides 4 to 738 of SEQ ID NO:134.

### Claim 16 (depends on 13)

The isolated polypeptide of claim 13, wherein said first sequence of (c) comprises a sequence encoded by nucleotides 85 to 738 of SEQ ID NO:134.

### Claim 17 (depends on 11, 12, 13, 14, 15)

The isolated polypeptide according to claim 11, 12, 13, 14, 15, or 16, wherein said immunoglobulin is IgG1.

### Claim 18

An isolated polypeptide comprising amino acids 29 to 246 of SEQ ID NO:135.

### Claim 19 (depends on 18)

The isolated polypeptide of claim 18, wherein said polypeptide comprises a sequence encoded by nucleotides 85 to 738 of SEQ ID NO:134.